{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:03:45Z","timestamp":1784527425977,"version":"3.55.0"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Liquid biopsy now provides minimally invasive access to tumor-derived genomic and epigenetic information across the lung cancer continuum, and its clinical role continues to expand. This review examines that role across cancer detection (screening and diagnosis), treatment monitoring (advanced-disease genotyping, minimal residual disease (MRD) assessment, and resistance profiling at progression), and clinical outcome prediction. Plasma-based genotyping is now well established in advanced non-small cell lung cancer (NSCLC), while circulating tumor DNA (ctDNA)-based MRD detection in the curative-intent setting has accumulated a substantial evidence base over the past 5\u00a0years. Cell-free DNA (cfDNA) methylation, fragmentomics, and circulating tumor RNA (ctRNA) are emerging as complementary modalities, particularly when tumor shedding is low. We also consider concordance between liquid and tissue biopsies, the use of cerebrospinal fluid (CSF) ctDNA in central nervous system (CNS)-involved disease, and the practical issues of cost, reimbursement, and access that shape clinical adoption. The current state of the field can be framed across three tiers of evidence, with established applications, applications under prospective evaluation, and applications not yet ready for routine clinical use. No multi-cancer early detection (MCED) test has shown a mortality benefit to date, and ctDNA-guided treatment changes in metastatic disease still lack randomized overall-survival data.<\/jats:p>","DOI":"10.3389\/fcell.2026.1874565","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:35:43Z","timestamp":1784525743000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction"],"prefix":"10.3389","volume":"14","author":[{"given":"Akshee","family":"Batra","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xena","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Morgenstern-Kaplan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey C.","family":"Thomson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mount Auburn Hospital, Beth Israel Lahey Health","place":["Cambridge, MA, United States"]},{"name":"Department of Medicine, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Lopes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinmay","family":"Jani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat. Commun."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e20536","article-title":"Accelerating treatment decisions with liquid biopsy NGS in non-small cell lung cancer","volume":"43","author":"Armas","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B4","volume-title":"A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy","year":"2024"},{"key":"B5","doi-asserted-by":"publisher","first-page":"eabc4308","DOI":"10.1126\/sciadv.abc4308","article-title":"A mathematical model of ctDNA shedding predicts tumor detection size","volume":"6","author":"Avanzini","year":"2020","journal-title":"Sci. Adv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","article-title":"Liquid biopsy epigenomic profiling for cancer subtyping","volume":"29","author":"Baca","year":"2023","journal-title":"Nat. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1001\/jama.2025.19798","article-title":"Lung cancer deaths prevented and life-years gained from lung cancer screening","volume":"334","author":"Bandi","year":"2025","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1038\/s41467-023-41774-w","article-title":"Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization","volume":"14","author":"Bie","year":"2023","journal-title":"Nat. Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma","volume":"31","author":"Black","year":"","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1016\/j.cell.2025.10.020","article-title":"Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction","volume":"188","author":"Black","year":"","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13046-025-03480-x","article-title":"Detecting actionable mutations from matched plasma-based versus tissue next-generation sequencing in advanced non-small cell lung cancer: a retrospective single center analysis on site","volume":"44","author":"Bontoux","year":"2025","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.3390\/cancers15153959","article-title":"Methylated circulating tumor DNA in blood as a tool for diagnosing lung cancer: a systematic review and meta-analysis","volume":"15","author":"Borg","year":"2023","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/1078-0432.CCR-25-0430","article-title":"The impact of concordance between liquid and tissue biopsy for actionable mutations: insights from the ROME trial","volume":"32","author":"Botticelli","year":"2026","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41698-025-00984-9","article-title":"A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer","volume":"9","author":"Boukouris","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9109","DOI":"10.1200\/JCO.2023.41.16_suppl.9109","article-title":"Contemporary biomarker testing rates in both early and advanced NSCLC: results from the MYLUNG pragmatic study","volume":"41","author":"Butrynski","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"751106","DOI":"10.3389\/fonc.2021.751106","article-title":"The landscape of actionable genomic alterations by Next- generation sequencing in tumor tissue Versus circulating tumor DNA in Chinese patients with non-small cell lung cancer","volume":"11","author":"Cai","year":"2021","journal-title":"Front. Oncol."},{"key":"B20","volume-title":"National Coverage Determination (NCD): Next Generation Sequencing (NGS) (90.2)","year":"2020"},{"key":"B21","volume-title":"Local Coverage Determination (LCD): MolDX \u2013 Minimal Residual Disease Testing for Cancer (L38835)","year":"2021"},{"key":"B22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov."},{"key":"B24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3892\/or.2023.8543","article-title":"Detecting liquid remnants of solid tumors treated with curative intent: circulating tumor DNA as a biomarker of minimal residual disease","volume":"49","author":"Chen","year":"2023","journal-title":"Oncol. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12916-023-02954-z","article-title":"Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer","volume":"21","author":"Chen","year":"","journal-title":"BMC Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","article-title":"Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer","volume":"41","author":"Chen","year":"","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40291-024-00725-x","article-title":"Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis","volume":"28","author":"Chen","year":"2024","journal-title":"Mol. Diagn Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5090\/jcs.25.017","article-title":"Low-dose computed tomography lung cancer screening for individuals who have never smoked: a review of recent updates in Taiwan and the United States","volume":"58","author":"Chung","year":"2025","journal-title":"J. Chest Surg."},{"key":"B29","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial","volume":"382","author":"de Koning","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2274123","DOI":"10.1080\/15384047.2023.2274123","article-title":"Clinical application of molecular residual disease detection by circulation tumor DNA in solid cancers and a comparison of technologies: review article","volume":"24","author":"Dong","year":"2023","journal-title":"Cancer Biol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"609","DOI":"10.6004\/jnccn.2023.7011","article-title":"Private payer and medicare coverage policies for use of circulating tumor DNA tests in cancer diagnostics and treatment","volume":"21","author":"Douglas","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"B34","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.modpat.2025.100744","article-title":"Clinicopathological predictors of the presence of blood circulating tumor DNA in early-stage non-small cell lung cancers","volume":"38","author":"Driussi","year":"2025","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"B35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.21037\/jtd-23-1827","article-title":"Cell-free DNA methylation profile potential in the diagnosis of lung squamous cell carcinoma","volume":"16","author":"Du","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jtho.2021.07.008","article-title":"Blood first assay screening trial (BFAST) in treatment-naive advanced or metastatic NSCLC: initial results of the phase 2 ALK-positive cohort","volume":"16","author":"Dziadziuszko","year":"2021","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.molmed.2024.03.007","article-title":"Cell-free DNA methylation in the clinical management of lung cancer","volume":"30","author":"Ezegbogu","year":"2024","journal-title":"Trends Mol. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"116699","DOI":"10.1016\/j.ejca.2026.116699","article-title":"Integrating liquid biopsies and artificial intelligence for early cancer detection: a systematic review and meta-analysis","volume":"239","author":"Filis","year":"2026","journal-title":"Eur. J. Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e2325332","DOI":"10.1001\/jamanetworkopen.2023.25332","article-title":"Association of circulating tumor DNA testing before tissue diagnosis with time to treatment among patients with suspected advanced lung cancer: the ACCELERATE nonrandomized clinical trial","volume":"6","author":"Garc\u00eda-Pardo","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/1878-0261.13468","article-title":"Detecting ALK, ROS1, and RET fusions and the MET\u0394ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques","volume":"17","author":"Gim\u00e9nez-Capit\u00e1n","year":"2023","journal-title":"Mol. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.21037\/tlcr-20-727","article-title":"Can autoantibody tests enhance lung cancer screening? an evaluation of EarlyCDT\u00ae-Lung in context of the German lung cancer screening intervention trial (LUSI)","volume":"10","author":"Gonz\u00e1lez","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"B43","volume-title":"Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate [Press Release]","year":"2026"},{"key":"B44","doi-asserted-by":"publisher","first-page":"190052","DOI":"10.1183\/16000617.0052-2019","article-title":"Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages","volume":"29","author":"Guibert","year":"2020","journal-title":"Eur. Respir. Rev. Off. J. Eur. Respir. Soc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1111\/cas.15084","article-title":"Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers","volume":"112","author":"Hasegawa","year":"2021","journal-title":"Cancer Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"100795","DOI":"10.1016\/j.jtocrr.2025.100795","article-title":"Longitudinal tracking of ALK-rearranged NSCLC from plasma using circulating tumor RNA and circulating tumor DNA","volume":"6","author":"Heeke","year":"2025","journal-title":"JTO Clin. Res. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1038\/s41591-025-03577-y","article-title":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer","volume":"31","author":"Herbst","year":"2025","journal-title":"Nat. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2025.43.16_suppl.8011","article-title":"ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab","volume":"43","author":"Horndalsveen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cllc.2024.10.013","article-title":"Brief report: methylation-based ctDNA serial monitoring correlates with immunotherapy response in NSCLC","volume":"26","author":"Hsiao","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e20614","DOI":"10.1200\/JCO.2023.41.16_suppl.e20614","article-title":"Early detection of lung cancer using a panel of circulating cell-free DNA methylation biomarkers","volume":"41","author":"Hu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1200\/JCO.2024.42.16_suppl.8078","article-title":"Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)","volume":"42","author":"Isbell","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jmoldx.2019.10.013","article-title":"Concordance of genomic alterations by next-generation sequencing in tumor tissue versus cell-free DNA in stage I-IV non-small cell lung cancer","volume":"22","author":"Jiang","year":"2020","journal-title":"J. Mol. Diagn"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jtho.2023.05.027","article-title":"Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stages I to IIIA EGFR-mutant non-small cell lung cancer","volume":"18","author":"Jung","year":"2023","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13059-022-02710-1","article-title":"Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from nanopore sequencing","volume":"23","author":"Katsman","year":"2022","journal-title":"Genome Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"oyag001","DOI":"10.1093\/oncolo\/oyag001","article-title":"DNA and RNA-based next-generation sequencing for companion diagnostic rearrangement detection in solid tumors","volume":"31","author":"Keller-Evans","year":"2026","journal-title":"Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"13502","DOI":"10.1038\/s41598-023-40611-w","article-title":"Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer","volume":"13","author":"Kwon","year":"2023","journal-title":"Sci. Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e21021","DOI":"10.1200\/JCO.2023.41.16_suppl.e21021","article-title":"A comparative analysis of next-generation sequencing based on plasma cfDNA and tumor tissue DNA in patients with advanced lung cancer","volume":"41","author":"Lin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"8377","DOI":"10.1002\/cam4.4339","article-title":"Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients","volume":"10","author":"Li","year":"2021","journal-title":"Cancer Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/cncr.33985","article-title":"Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer","volume":"128","author":"Li","year":"2022","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.7150\/thno.28119","article-title":"Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA)","volume":"9","author":"Liang","year":"2019","journal-title":"Theranostics"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e70160","DOI":"10.1002\/ctm2.70160","article-title":"LcProt: proteomics-based identification of plasma biomarkers for lung cancer multievent, a multicentre study","volume":"15","author":"Liang","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"107282","DOI":"10.1016\/j.lungcan.2023.107282","article-title":"Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer","volume":"182","author":"Lin","year":"2023","journal-title":"Lung Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12885-023-10997-x","article-title":"Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study","volume":"23","author":"Lococo","year":"2023","journal-title":"BMC Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e2500489","DOI":"10.1200\/PO-25-00489","article-title":"Predictive effectiveness of circulating tumor DNA in recurrent early-stage non-small cell lung cancer: an updated meta-analysis","volume":"9","author":"Lu","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/1878-0261.70145","article-title":"Liquid biopsy epigenetics: establishing a molecular profile based on cell-free DNA","volume":"20","author":"Maansson","year":"2026","journal-title":"Mol. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13643-025-02860-w","article-title":"Circulating cell-free DNA methylation as biomarker for lung cancer detection: a systematic review and meta-analysis of diagnostic studies","volume":"14","author":"Machado","year":"2025","journal-title":"Syst. Rev."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.3390\/cancers16213641","article-title":"The evidence base for circulating tumor DNA-methylation in non-small cell lung cancer: a systematic review and meta-analysis","volume":"16","author":"Maffeo","year":"2024","journal-title":"Cancers"},{"key":"B70","doi-asserted-by":"publisher","first-page":"106029","DOI":"10.1016\/j.esmoop.2025.106029","article-title":"Liquid biopsy and tissue biopsy for the detection of EGFR mutations in patients with stage III non-small-cell lung cancer: an observational real-world study","volume":"11","author":"Malapelle","year":"2026","journal-title":"ESMO Open"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1038\/s41591-025-03918-x","article-title":"Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial","volume":"31","author":"Marchetti","year":"2025","journal-title":"Nat. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e0295987","DOI":"10.1371\/journal.pone.0295987","article-title":"Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes","volume":"19","author":"May","year":"2024","journal-title":"PloS One"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e0166354","DOI":"10.1371\/journal.pone.0166354","article-title":"Performance of streck cfDNA blood collection tubes for liquid biopsy testing","volume":"11","author":"Medina","year":"2016","journal-title":"PLoS One"},{"key":"B74","doi-asserted-by":"publisher","first-page":"101279","DOI":"10.1016\/j.tranon.2021.101279","article-title":"Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in non-small cell lung cancer","volume":"15","author":"Metzenmacher","year":"2022","journal-title":"Transl. Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B76","volume-title":"Safety and Performance of a Multi- Cancer Early Detection (MCED) Test in an Intended-Use Population: Initial Results from the Registrational PATHFINDER 2 Study [late-breaking abstract LBA64]","author":"Nabavizadeh","year":"2025"},{"key":"B77","volume-title":"Natera Announces Medicare Coverage of Signatera for Surveillance in Lung Cancer","year":"2025"},{"key":"B78","volume-title":"Central Nervous System Cancers [Clinical Practice Guidelines in Oncology, version 3.2025]","year":"2025"},{"key":"B79","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Non-Small Cell Lung Cancer Version 5.2026","year":"2026"},{"key":"B80","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-024-00985-w","article-title":"Circulating tumor DNA in early stage and locally advanced NSCLC: ready for clinical implementation?","volume":"22","author":"Normanno","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"200","DOI":"10.18632\/oncotarget.28565","article-title":"Analytical validation of NeXT personal\u00ae, an ultra-sensitive personalized circulating tumor DNA assay","volume":"15","author":"Northcott","year":"2024","journal-title":"Oncotarget"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1186\/s12885-025-14583-1","article-title":"Cerebrospinal fluid circulating tumor DNA (ctDNA) as a biomarker for CNS metastases in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis comparing CSF ctDNA and traditional methods","volume":"25","author":"Olayode","year":"2025","journal-title":"BMC Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-0716-4192-7_5","article-title":"Whole genome methylation sequencing via enzymatic conversion (EM-seq): protocol, data processing, and analysis","volume":"2866","author":"Olova","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","article-title":"Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients","volume":"41","author":"Pan","year":"2023","journal-title":"Cancer Cell"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/cancers17081340","article-title":"Identification of driver mutations and risk stratification in lung adenocarcinoma via liquid biopsy","volume":"17","author":"Pathak","year":"2025","journal-title":"Cancers"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-25-0960","article-title":"ELIOS: a multicenter, molecular profiling study of patients with EGFR-mutant advanced non-small cell lung cancer treated with first-line osimertinib","volume":"6","author":"Piotrowska","year":"2026","journal-title":"Cancer Discov."},{"key":"B88","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2025.43.16_suppl.3016","article-title":"Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay","volume":"43","author":"Poh","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1158\/1078-0432.CCR-25-2958","article-title":"Minimal residual disease enhances prognostic stratification beyond pathologic response in resectable Non- small cell lung cancer","volume":"32","author":"Provencio","year":"2026","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat. Commun."},{"key":"B91","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10020-021-00331-1","article-title":"Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer","volume":"27","author":"Qvick","year":"2021","journal-title":"Mol. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1002\/mco2.401","article-title":"Epigenetic regulation in lung cancer","volume":"4","author":"Ramazi","year":"2021","journal-title":"MedComm"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat. Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"108528","DOI":"10.1016\/j.lungcan.2025.108528","article-title":"ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach","volume":"203","author":"Rosenlund","year":"2025","journal-title":"Lung Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC Post- osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1182\/blood.2019003976","article-title":"Lessons to learn from tumor-educated platelets","volume":"137","author":"Roweth","year":"2021","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e2500181","DOI":"10.1200\/PO-25-00181","article-title":"Prospective multicenter study evaluating a combined circulating tumor DNA and circulating tumor RNA liquid biopsy in metastatic non-small cell lung cancer (LIQUIK)","volume":"9","author":"Samol","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","article-title":"Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study","volume":"402","author":"Schrag","year":"2023","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e1004574","DOI":"10.1371\/journal.pmed.1004574","article-title":"Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: a retrospective validation study","volume":"22","author":"Schuurbiers","year":"2025","journal-title":"PLoS Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/annonc\/mdy544","article-title":"Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases","volume":"30","author":"Seoane","year":"2019","journal-title":"Ann. Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","article-title":"Sensitive tumour detection and classification using plasma cell-free DNA methylomes","volume":"563","author":"Shen","year":"2018","journal-title":"Nature"},{"key":"B104","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cllc.2023.09.005","article-title":"TARGET: a phase II, open-label, Single- arm study of 5-Year adjuvant osimertinib in completely resected EGFR-mutated stage II to IIIB NSCLC post complete surgical resection","volume":"25","author":"Soo","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00191","article-title":"Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance","volume":"3","author":"Stetson","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A large-scale prospective concordance study of Plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid)","volume":"29","author":"Sugimoto","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2000670","DOI":"10.1183\/13993003.00670-2020","article-title":"Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging","volume":"57","author":"Sullivan","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s11060-025-05224-5","article-title":"Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis","volume":"175","author":"Sun","year":"2025","journal-title":"J. Neurooncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1002\/cncr.32749","article-title":"Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan oncology group 8815L\/LPS study","volume":"126","author":"Takahama","year":"2020","journal-title":"Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/cncr.35263","article-title":"Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer","volume":"130","author":"Tan","year":"2024","journal-title":"Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1158\/1078-0432.CCR-25-3384","article-title":"Epigenetic instability-based metrics in Cell- free DNA for early cancer detection","volume":"32","author":"Thursby","year":"2026","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"B112","volume-title":"List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)","year":"2026"},{"key":"B113","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for lung cancer: US preventive services task force recommendation statement","volume":"325","author":"Krist","year":"2021","journal-title":"JAMA"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1101\/gr.266551.120","article-title":"Enzymatic methyl sequencing detects DNA methylation at single-base resolution from picograms of DNA","volume":"31","author":"Vaisvila","year":"2021","journal-title":"Genome Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1758835920974192","DOI":"10.1177\/1758835920974192","article-title":"Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment","volume":"12","author":"Vendrell","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1186\/s12885-020-07445-5","article-title":"Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma","volume":"20","author":"Verma","year":"2020","journal-title":"BMC Cancer"},{"key":"B117","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.jlb.2023.100130","article-title":"Plasma cell-free RNA PD-L1 or tissue PD-L1 protein expression and outcomes with first-line immunotherapy in metastatic non-small cell lung cancer","volume":"3","author":"Walker","year":"2024","journal-title":"J. Liq. Biopsy"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1164\/rccm.202109-2019OC","article-title":"Multidimensional cell-free DNA fragmentomic assay for detection of early-stage lung cancer","volume":"207","author":"Wang","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-024-03040-4","article-title":"Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment","volume":"30","author":"Widman","year":"2024","journal-title":"Nat. Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3322\/caac.21811","article-title":"Screening for lung cancer: 2023 guideline update from the American cancer society","volume":"74","author":"Wolf","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B121","doi-asserted-by":"publisher","first-page":"e250002","DOI":"10.6004\/jnccn.2025.0002","article-title":"NCCN guidelines\u00ae insights: Lung cancer screening, version 1.2025","volume":"23","author":"Wood","year":"2025","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B122","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-Based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/jnci\/djaf061","article-title":"Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study)","volume":"117","author":"Xia","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"B125","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1038\/s41598-025-90013-3","article-title":"Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring","volume":"15","author":"Ye","year":"2025","journal-title":"Sci. Rep."},{"key":"B126","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fimmu.2020.02024","article-title":"Immunoregulatory roles of extracellular vesicles and associated therapeutic applications in lung cancer","volume":"11","author":"Yin","year":"2020","journal-title":"Front. Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s43018-026-01116-3","article-title":"A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection","volume":"7","author":"Zeng","year":"2026","journal-title":"Nat. Cancer"},{"key":"B128","doi-asserted-by":"publisher","first-page":"103892","DOI":"10.1016\/j.clon.2025.103892","article-title":"Postoperative circulating tumor DNA in predicting recurrence of non-small cell lung cancer: a systematic review and meta-analysis","volume":"44","author":"Zhang","year":"2025","journal-title":"Clin. Oncol. R. Coll. Radiol. G B."},{"key":"B129","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2019.05.034","article-title":"Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer","volume":"134","author":"Zhang","year":"2019","journal-title":"Lung Cancer"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cllc.2023.09.008","article-title":"Adjuvant therapy-free strategy for stage IB to IIIA non-small-cell lung cancer patients after radical resection based on longitudinal undetectable molecular residual disease: prospective, multicenter, single-arm study (CTONG 2201)","volume":"25","author":"Zhang","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-24-2909","article-title":"Follow-up analysis enhances understanding of molecular residual disease in localized non-small cell lung cancer","volume":"31","author":"Zhang","year":"","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40291-023-00670-1","article-title":"Personalized cancer monitoring assay for the detection of ctDNA in patients with solid tumors","volume":"27","author":"Zhao","year":"2023","journal-title":"Mol. Diagn Ther."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41591-025-03538-5","article-title":"Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases","volume":"31","author":"Zheng","year":"2025","journal-title":"Nat. Med."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1874565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:35:47Z","timestamp":1784525747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1874565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":133,"alternative-id":["10.3389\/fcell.2026.1874565"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1874565","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"article-number":"1874565"}}